Market Signal Briefing

NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your Firefly Aerospace (“Firefly” or the “Company”) (NASDAQ:FLY) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost.

Investors have until January 12, 2026 to ask the Court to appoint them as lead plaintiff.

[CONTACT THE FIRM IF YOU SUFFERED A LOSS]

What Is The Lawsuit About?

The lawsuit has been filed on behalf of investors who purchased securities during the period of August 7, 2025 through September 29, 2025, inclusive (“the Class Period”). The lawsuit alleges that: (i) the Offering Documents for Firefly’s August 2025 initial public offering contained untrue statements of material fact or omitted to state other facts necessary to make the statements made not misleading and were not prepared in accordance with the rules and regulations governing their preparation; (ii) Firefly had overstated the demand and growth prospects for its Spacecraft Solutions offerings; and (iii) Firefly had overstated the operational readiness and commercial viability of its Alpha rocket program.

Firefly conducted its IPO on August 7, 2025, selling 19.296 million shares of common stock priced at $45.00 per share.

On September 22, 2025, Firefly reported its financial results for the second quarter of 2025, its first earnings report as a public company. Among other items, Firefly reported a loss of $80.3 million, or $5.78 per share, compared to $58.7 million, or $4.60 per share, for the same quarter in 2024. Firefly also reported revenue of $15.55 million, below analyst estimates of $17.25 million and down 26.2% from the same quarter in 2024. Significantly, Firefly reported revenue of only $9.2 million in its Spacecraft Solutions business segment, representing a 49% year-over-year decrease. On this news, the price of Firefly shares declined by $7.58 per share, or approximately 15.3%, from $49.52 per share on September 22, 2025 to close at $41.94 on September 23, 2025.

On September 29, 2025, Firefly disclosed that “the first stage of Firefly's Alpha Flight 7 rocket experienced an event that resulted in a loss of the stage.” Notably, Firefly CEO Jason Kim stated during the September 22, 2025 earnings call that the Company “expect[ed] to launch Flight 7 in the coming weeks.” Following on the heels of Firefly’s failed April 2025 Alpha rocket launch, the Alpha 7 test failure raised significant questions about Firefly’s ability to meet its commercial launch commitments and the viability of the Company’s technology. On this news, the price of Firefly shares declined by $7.64 per share, or approximately 20.7%, from $36.96 per share on September 29, 2025 to close at $29.32 on September 30, 2025.

[CLICK HERE TO LEARN MORE ABOUT THE CLASS ACTION]

What Should I Do?

If you purchased or otherwise acquired Firefly securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[WHAT IS A SECURITIES CLASS ACTION?]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds Inspire Medical Systems, Inc. (“Inspire” or the “Company”) (NYSE:INSP) investors of the January 5, 2026deadline to seek the role of lead plaintiff in a pending federal securities class action.

If you purchased or otherwise acquired Inspire securities, have information, or would like to learn more, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the form below, to discuss your rights or interests.

[CONTACT THE FIRM IF YOU SUFFERED A LOSS]

What Is The Lawsuit About?

The lawsuit has been filed on behalf of investors who purchased securities during the period of August 6, 2024 through August 4, 2025, inclusive (“the Class Period”). The lawsuit alleges The lawsuit alleges that Defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) demand for Inspire, an implantable medical device for the treatment of obstructive sleep apnea which uses an implanted sensor and neurostimulator designed to improve respiration during sleep, was poor, as providers had significant amounts of surplus inventory and were reluctant to transition to a new treatment; and (ii) contrary to Defendants’ statements assuring investors that Inspire Medical had taken all necessary steps to ensure a successful launch and, later, that the launch was in fact proceeding successfully – Inspire Medical had failed to complete basic tasks that were essential predicates to launch.

On August 4, 2025, the Company revealed that the Inspire V launch was facing an “elongated timeframe” because, among other issues, “many centers [had not] complete[d] the training, contracting and onboarding criteria required prior to the purchase and implant of Inspire V.” That same day, Defendants further admitted that “software updates for claims submissions and processing did not take effect until July 1,” which meant that “implanting centers [were] not … able to bill for those procedures until July 1.” As a result, many treatment centers chose to continue to treat with and earlier version of Inspire. Finally, Defendants revealed that the Inspire V rollout was plagued by poor demand resulting from excess inventory, and the Company reduced its 2025 earnings guidance by more than 80%. On this news, the price of Inspire shares declined by $42.04 per share, or approximately 32.35%, from $129.95 per share on August 4, 2025, to close at $87.91 on August 5, 2025.

[CLICK HERE TO LEARN MORE ABOUT THE CLASS ACTION]

What Should I Do?

If you purchased or otherwise acquired Inspire securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[WHAT IS A SECURITIES CLASS ACTION?]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts
Kirby McInerney LLP        
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
[email protected]

Ryman Healthcare Limited (OTCPK:RYHTY) Q2 2026 Earnings Call November 26, 2025 5:00 PM EST

Company Participants

Naomi James - Chief Executive Officer
Hayden Strickett
Matthew Prior - Chief Financial Officer

Conference Call Participants

Bianca Fledderus - UBS Investment Bank, Research Division
Arie Dekker - Jarden Limited, Research Division
Will Twiss - Forsyth Barr Group Ltd., Research Division
Stephen Ridgewell - Craigs Investment Partners Limited, Research Division
Nick Mar - Macquarie Research

Presentation

Operator

Thank you for standing by, and welcome to the Ryman Healthcare Half Year Results Briefing. [Operator Instructions] I would now like to hand the conference over to Ms. Naomi James, Chief Executive Officer. Please go ahead.

Naomi James
Chief Executive Officer

Good morning, everyone. I'm Naomi James, Chief Executive Officer of Ryman Healthcare. Thank you for joining us for our half year results for the 6 months to 30 September 2025. With me today is Matt Prior, who commenced as Chief Financial Officer on the 31st of July; and Hayden Strickett, our Head of Investor Relations. We're going to be working to get through the presentation in around 30 minutes to allow time for Q&A before we wrap up at midday. Looking at the agenda, I'll provide an overview of sales, stock, operations and development before handing to Matt, who will speak to the financials and capital management. And I'll then provide an update on outlook and strategic priorities before opening up for Q&A.

Hayden Strickett

Starting on Slide 4. As you'll see from today's results, we are well on our way to delivering better returns and are doing the things we said we would do when we raised capital at the start of the year. This is the first positive free cash flow result that Ryman has announced in more than a decade. We have made substantial progress towards achieving our cost reduction

Recommended For You

, /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Sprouts Farmers Market, Inc. (NASDAQ: SFM) securities between June 4, 2025 and October 29, 2025. Sprouts is a specialty grocery store chain that operates in the U.S.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

The Allegations: Robbins LLP is Investigating Allegations that Sprouts Famers Market, Inc. (SFM) Misled Investors Regarding its Growth Potential

According to the complaint, defendants provided investors with material information concerning Sprouts' growth potential for the fiscal year 2025. Defendants' statements included, among other things, confidence in the Company's customer base to remain resilient to macroeconomic pressures and that Sprouts would instead benefit from the perceived tailwinds from a more cautious consumer. At the same time, defendants concealed material adverse facts concerning the true state of Sprouts' growth potential; notably, that a more cautious consumer could result in significant slowdown in sales growth and the purported tailwinds with be unable to dampen the slowdown or would otherwise fail to manifest entirely.

On October 29, 2025, Sprouts announced disappointing top-line results for the third quarter of fiscal 2025 with comparable stores growth faltering below Company expectations. Sprouts further announced disappointing fourth quarter guidance and further slashed its full year estimates, despite raising them only one quarter prior. The Company attributed its results and lowered guidance on "challenging year-on-year comparisons as well as signs of a softening consumer." On this news, the price of Sprouts' common stock fell from a closing market price of $104.55 per share on October 29, 2025, to $77.25 per share on October 30, 2025, a decline of about 26.11%.

What Now: You may be eligible to participate in the class action against Sprouts Farmers Market, Inc. Shareholders who wish to serve as lead plaintiff for the class should contact Robbins LLP. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.  You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses. 

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. 

To be notified if a class action against Sprouts Farmers Market, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising.  Past results do not guarantee a similar outcome.  

SOURCE Robbins LLP

VANCOUVER, British Columbia, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Fortuna Mining Corp. (NYSE: FSM | TSX: FVI) is pleased to announce that, in accordance with National Instrument 43-101 -  Standards of Disclosure for Mineral Projects, it has filed the technical report entitled “Diamba Sud Gold Project, Kédougou Region, Senegal”, with an effective date of October 15, 2025  (the “Technical Report”), supporting the results of the Preliminary Economic Assessment (PEA) previously announced in Fortuna’s news release dated October 15, 2025.

The Technical Report is available on the Company’s website, on SEDAR+ and on EDGAR under the Company’s profile.  

About Fortuna Mining Corp.

Fortuna Mining Corp. is a Canadian precious metals mining company with three operating mines and a portfolio of exploration projects in Argentina, Côte d'Ivoire, Mexico, and Peru, as well as the Diamba Sud Gold Project in Senegal. Sustainability is at the core of our operations and stakeholder relationships. We produce gold and silver while creating long-term shared value through efficient production, environmental stewardship, and social responsibility. For more information, please visit our website at www.fortunamining.com

ON BEHALF OF THE BOARD

Jorge A. Ganoza
President, CEO, and Director
Fortuna Mining Corp.

Investor Relations:

Carlos Baca | [email protected] | fortunamining.com | X | LinkedIn | YouTube

Users on social media posted that they were experiencing issues with Netflix's service on Wednesday, the night of the widely anticipated "Stranger Things" fifth-season premiere.

DownDetector.com on Wednesday said "User reports indicate problems at Netflix."

"Netflix fix your app bro," one X user posted.

Users began reporting issues with Netflix around 7:40 p.m. Eastern, according to DownDetector.com. Netflix had said the latest season of "Stranger Things" would go live Wednesday at 8 p.m. Eastern.

Netflix said it would release the first four episodes of the "Stranger Things" fifth season on Wednesday. The streaming service has said it will release another three episodes on Dec. 25 and the final episode of the show on Dec. 31.

The company did not respond to a request for comment.

This is a breaking story. Check back for updates.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

In the latest close session, Carnival (CCL - Free Report) was down 1.13% at $25.43. The stock's change was less than the S&P 500's daily gain of 0.69%. Meanwhile, the Dow gained 0.67%, and the Nasdaq, a tech-heavy index, added 0.82%.

The cruise operator's stock has dropped by 7.68% in the past month, falling short of the Consumer Discretionary sector's loss of 4.51% and the S&P 500's loss of 0.31%.

The investment community will be paying close attention to the earnings performance of Carnival in its upcoming release. It is anticipated that the company will report an EPS of $0.24, marking a 71.43% rise compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $6.36 billion, indicating a 7.13% upward movement from the same quarter last year.

CCL's full-year Zacks Consensus Estimates are calling for earnings of $2.17 per share and revenue of $26.64 billion. These results would represent year-over-year changes of +52.82% and +6.49%, respectively.

Investors should also take note of any recent adjustments to analyst estimates for Carnival. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.

The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Carnival presently features a Zacks Rank of #3 (Hold).

Investors should also note Carnival's current valuation metrics, including its Forward P/E ratio of 11.88. This represents a discount compared to its industry average Forward P/E of 18.74.

It's also important to note that CCL currently trades at a PEG ratio of 0.53. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Leisure and Recreation Services industry currently had an average PEG ratio of 1.15 as of yesterday's close.

The Leisure and Recreation Services industry is part of the Consumer Discretionary sector. With its current Zacks Industry Rank of 146, this industry ranks in the bottom 41% of all industries, numbering over 250.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

AG META expands its real-world asset tokenization infrastructure as global digital finance adoption continues to grow.

November 26, 2025 18:56 ET

 | Source:

AG META

London, United Kingdom, Nov. 26, 2025 (GLOBE NEWSWIRE) -- AG META announced the launch of an updated version of its real-world asset tokenization infrastructure, marking a timely advancement in the company’s operational framework. The update introduces newly deployed verification modules, expanded asset category registration tools, and improved processing capacity across its global node network. These updates reflect AG META’s response to the growing demand for digital asset systems as global financial structures continue shifting toward digital formats.

According to the company, the latest infrastructure update includes enhanced identity verification processes, expanded compliance automation features, and new multi-category asset onboarding capabilities that support a wider range of real-world assets. AG META reports that these improvements are now active and available to issuers and institutional users evaluating blockchain-based asset registration and verification models. With these updates live, the company states that tokenization has moved from early exploration to broader operational adoption among its partners.

The rapid growth of digital finance has increased demand for systems that support secure, transparent and compliant management of traditional assets on chain. AG META positions its platform as a structured environment that assists issuers and investors in converting real-world assets into digital representations supported by standardized verification and operational controls.

According to AG META, improvements in regulatory clarity and the gradual acceptance of digital asset frameworks have contributed to a rise in tokenization activity across several categories. These include real estate, private credit, mineral resources, commodities, artwork and corporate debt. Converting these assets into digital formats allows for clearer record keeping, more accessible participation models and simplified settlement processes.

AG META states that its platform is designed to address long-standing challenges associated with traditional asset management. These challenges include high participation thresholds, limited liquidity, lengthy administrative steps and rising operational costs. By supporting digital issuance, verification, settlement, custody and transfer processes within a unified system, the company aims to create a more efficient structure for organizations exploring real-world asset strategies.

Based in the United Kingdom, AG META follows the region’s regulatory standards within its approach to compliance auditing procedures and identity verification. The company highlights several primary features of its platform that support digital asset operations. These include multi category asset support for registration and fractional ownership, a global node network intended to improve processing speed, compliance workflows aligned with know your customer and anti-money laundering requirements, and multilayered security controls. The platform also incorporates encrypted data handling, distributed storage, secure node architecture, and independent smart contract evaluation.

AG META states that it plans to broaden its collaboration with asset issuing entities, financial institutions, technical service providers and international participants as interest in real-world asset tokenization continues to grow. The company reports that global digital finance adoption is accelerating and that tokenized asset models may become a standard component of future financial infrastructure.

About AG META

AG META is a United Kingdom-based digital asset platform that provides real-world asset tokenization services, digital certificate issuance, asset auditing, custody solutions, blockchain settlement and liquidity support. The company focuses on enabling secure and transparent digital management of traditional assets.

Contact Data

info.agmeta.com
https://agmeta.com/

Is Donaldson Company a stock worth your attention? Join our experts as they break down its strengths, management, and financials to help you decide if it belongs in your portfolio.

Explore the exciting world of Donaldson Company (DCI 0.40%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
*Stock prices used were the prices of Oct. 15, 2025. The video was published on Nov. 25, 2025.

Anand Chokkavelu has no position in any of the stocks mentioned. Matt Frankel, CFP has no position in any of the stocks mentioned. Travis Hoium has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Donaldson. The Motley Fool has a disclosure policy.

November 26, 2025 19:00 ET

 | Source:

HUTCHMED (China) Limited

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 27, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology (“ESMO”) Asia Congress 2025, taking place on December 5-7, 2025 in Singapore, and the American Society of Hematology (“ASH”) Annual Meeting taking place on December 6-9, 2025 in Orlando, USA.

Results from a first-in-human study of the anti-CD47 monoclonal antibody HMPL-A83 in advanced solid tumors, as well as from the phase II part of the FRUSICA-2 registration study of the fruquintinib and sintilimab combination as a second-line treatment for locally advanced or metastatic renal cell carcinoma, will be presented at the ESMO Asia Congress 2025. Results from the phase II part of the phase II/III study of surufatinib in combination with camrelizumab and chemotherapy as a first-line treatment for metastatic pancreatic cancer will also be reported. Details of the presentations are as follows:

Abstract titlePresenter/Lead authorPresentation detailsESMO Asia Congress 2025 - SPONSORED STUDIES  A first-in-human (FIH), dose escalation study of HMPL-A83 (A83), an anti-CD47 monoclonal antibody (mAb) in patients (pts) with advanced solid tumors
Ye Guo
(Shanghai, China)162MO | Mini Oral session: Developmental therapeutics and precision medicine
Sunday, December 7, 2025
11:40 - 11:45 SGT
Hall 407Fruquintinib monotherapy as second-line (2L) treatment in locally advanced or metastatic renal cell carcinoma (RCC): results from phase 2 part of FRUSICA-2Shanshan Wang 
(Shanghai, China)
540O | Proffered Paper session: Genitourinary tumours
Friday, December 5, 2025
14:55 - 15:05 SGT
Hall 402Surufatinib (S) in combination with camrelizumab (C), nab-paclitaxel and gemcitabine (AG) as the first-line treatment in metastatic pancreatic cancer: results from phase 2 part of a randomized, open-label, active-controlled, phase 2/3 studyShukui Qin 
(Nanjing, China)
375P | Poster Display: Gastrointestinal tumours, non‑colorectalOsimertinib (osi) + savolitinib (savo) in EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) with MET overexpression and/or amplification (OverExp/Amp) following progressive disease (PD) on osi: SAVANNAH Asian subsetSe-Hoon Lee 
(Seoul, Korea)
982P | Poster Display:
Thoracic tumours, metastaticPatient-relevant Outcomes (PROs) from SACHI: a Phase 3 Trial of Savolitinib (Savo) plus Osimertinib (Osi) versus Chemotherapy (Chemo) in EGFR-mutant (EGFRm) and MET-amplified (METamp) Advanced NSCLC after Progression on EGFR-TKIsYongfeng Yu 
(Shanghai, China)
984P | Poster Display:
Thoracic tumours, metastaticAnalysis of MET Amplification (METamp) with FISH and NGS Method in SACHI TrialLonghua Sun 
(Nanchang, China)988P | Poster Display:
Thoracic tumours, metastaticProgression pattern in patients (pts) with EGFR-mutant (EGFRm), MET-amplified (METamp) advanced NSCLC treated with savolitinib (savo) plus osimertinib (osi)Haiyan Yang 
(Changsha, China)
1002P | Poster Display:
Thoracic tumours, metastaticMET testing and treatment (tx) sequencing after progression of disease (PD) on first-line (1L) osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and acquired MET overexpression and/or amplification (OverExp/Amp): Final analysis of a global real-world (rw) studyJulia Rotow 
(Boston, US)
1005P | Poster Display:
Thoracic tumours, metastatic   ESMO Asia Congress 2025 - INVESTIGATOR-INITIATED STUDIES  Fruquintinib Combined with TAS-102 with or without SBRT as Third- or Later-Line Treatment in Metastatic Colorectal Cancer: Preliminary Results from a Prospective Phase II TrialChen Zhang/ Yi Wang
(Ningbo, China)205P | Poster Display: Gastrointestinal tumours, colorectalEfficacy and safety of fruquintinib combined with PD-1 inhibitor and chidamide in MSS mCRC: a comparison with real-world bevacizumab plus anti-pd-1 and chidamide armGuanghai Dai/ Miaomiao Gou
(Beijing, China)
245eP | Poster Display: Gastrointestinal tumours, colorectalThe Efficacy and Safety of Fruquintinib (F) Plus FOLFIRI as Second-line  (2L) Treatment in Bevacizumab (Bev)-pretreated RAS-mutated (RAS‑m) Metastatic Colorectal Cancer (mCRC)Zhenyang Liu/ Xiaolin Yang
(Changsha, China)250eP | Poster Display: Gastrointestinal tumours, colorectalReal-world Observational Study of Fruquintinib in Combination with Irinotecan and Capecitabine as Second-line Treatment in Patients with Advanced Colorectal CancerXiujuan Qu/ Lin Xu
(Shenyang, China)255eP | Poster Display: Gastrointestinal tumours, colorectalMatching-Adjusted Indirect Comparison of Surufatinib versus High-Dose Octreotide LAR in Advanced Extrapancreatic Neuroendocrine TumorsJianming Xu 
(Beijing, China)214P | Poster Display: Gastrointestinal tumours, colorectalEfficacy and safety of surufatinib in combination with CAPTEM as conversion therapy in patients with unresectable pancreatic neuroendocrine tumors (pNETs): Data updates from a prospective, open-label studyXubao Liu/ Ziyao Wang 
(Chengdu, China)
400P | Poster Display: Gastrointestinal tumours, non‑colorectal    Final analysis of long-term results of sovleplenib’s ESLIM-01 China Phase III study in in adult patients with chronic primary immune thrombocytopenia will be presented at the 2025 ASH Annual Meeting. Details of the presentation is as follows:

Abstract titlePresenter/Lead authorPresentation details2025 ASH Annual Meeting - SPONSORED STUDIES  Phase 3 ESLIM-01 study: Final analysis of efficacy and safety of long-term treatment with sovleplenib in adults with chronic primary immune thrombocytopenia
Renchi Yang
(Tianjin, China)843 | Oral Abstract Session
Monday, December 8, 2025
15:15 - 15:30 EST
Room OCCC - W304EFGH    About Fruquintinib

Fruquintinib is a selective oral inhibitor of all three vascular endothelial growth factor receptors (“VEGFR”) -1, ‑2 and -3. Fruquintinib is co-developed and co-commercialized in China by HUTCHMED and Eli Lilly and Company under the brand name ELUNATE®. Takeda holds the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside mainland China, Hong Kong and Macau, marketing it under the brand name FRUZAQLA®.

About HMPL-A83

HMPL-A83 is an investigational IgG4-type humanized anti-CD47 monoclonal antibody that exhibits high affinity for CD47. HMPL-A83 blocks CD47 binding to Signal regulatory protein (SIRP) α and disrupts the “do not eat me” signal that cancer cells use to shield themselves from the immune system. HUTCHMED currently retains all rights to HMPL-A83 worldwide.

About Savolitinib

Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression. Savolitinib is being jointly developed by AstraZeneca and HUTCHMED, and commercialized by AstraZeneca under the brand name ORPATHYS®.

About Surufatinib

Surufatinib is a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with VEGFRs and fibroblast growth factor receptor (FGFR), which both inhibit angiogenesis, and colony stimulating factor-1 receptor (CSF-1R), which regulates tumor-associated macrophages, promoting the body’s immune response against tumor cells. Surufatinib is marketed in China by HUTCHMED under the brand name SULANDA®. HUTCHMED currently retains all rights to surufatinib worldwide.

About Sovleplenib

Sovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting the spleen tyrosine kinase, also known as Syk. Syk is a major component in B-cell receptor and Fc receptor signaling and is an established target for the treatment of multiple subtypes of B-cell lymphomas and autoimmune disorders. HUTCHMED currently retains all rights to sovleplenib worldwide.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:​HCM; HKEX:​13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including but not limited to its expectations regarding the therapeutic potential of fruquintinib, HMPL-A83, surufatinib, savolitinib and sovleplenib, the further clinical development for fruquintinib, HMPL-A83, surufatinib, savolitinib and sovleplenib, its expectations as to whether any studies on fruquintinib, HMPL-A83, surufatinib, savolitinib and sovleplenib would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of fruquintinib, HMPL-A83, surufatinib, savolitinib and sovleplenib, including as combination therapies, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential markets of fruquintinib, HMPL-A83, surufatinib, savolitinib and sovleplenib for a targeted indication, and the sufficiency of funding. In addition, as certain studies rely on the use of other drug products such as camrelizumab and osimertinib as combination therapeutics, such risks and uncertainties include assumptions regarding their safety, efficacy, supply and continued regulatory approval. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CONTACTS

Investor Enquiries+852 2121 8200 / [email protected]  Media Enquiries FTI Consulting –+44 20 3727 1030 / [email protected] Atwell / Tim Stamper+44 7771 913 902 (Mobile) / +44 7421 898 348 (Mobile)Brunswick – Zhou Yi+852 9783 6894 (Mobile) / [email protected]  Panmure LiberumNominated Advisor and Joint BrokerAtholl Tweedie / Emma Earl / Rupert Dearden+44 20 7886 2500  CavendishJoint BrokerGeoff Nash / Nigel Birks+44 20 7220 0500  Deutsche NumisJoint BrokerFreddie Barnfield / Jeffrey Wong / Duncan Monteith+44 20 7260 1000  

In the latest trading session, Kroger (KR - Free Report) closed at $67.03, marking a +1.33% move from the previous day. The stock's performance was ahead of the S&P 500's daily gain of 0.69%. Meanwhile, the Dow gained 0.67%, and the Nasdaq, a tech-heavy index, added 0.82%.

The supermarket chain's shares have seen a decrease of 2.28% over the last month, not keeping up with the Retail-Wholesale sector's loss of 1.21% and the S&P 500's loss of 0.31%.

Investors will be eagerly watching for the performance of Kroger in its upcoming earnings disclosure. The company is predicted to post an EPS of $1.04, indicating a 6.12% growth compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $34.31 billion, up 2.02% from the year-ago period.

Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $4.79 per share and revenue of $148.79 billion. These totals would mark changes of +7.16% and +1.13%, respectively, from last year.

Investors might also notice recent changes to analyst estimates for Kroger. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.

The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Kroger is currently sporting a Zacks Rank of #3 (Hold).

Valuation is also important, so investors should note that Kroger has a Forward P/E ratio of 13.82 right now. This expresses a discount compared to the average Forward P/E of 14.89 of its industry.

One should further note that KR currently holds a PEG ratio of 1.92. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Retail - Supermarkets industry had an average PEG ratio of 2.21 as trading concluded yesterday.

The Retail - Supermarkets industry is part of the Retail-Wholesale sector. This industry currently has a Zacks Industry Rank of 75, which puts it in the top 31% of all 250+ industries.

The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Baidu, Inc. (“Baidu” or the “Company”) (NASDAQ: BIDU) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN BAIDU, INC. (BIDU), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmit.

November 26, 2025 7:12 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - November 26, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Freeport-McMoRan Inc. (NYSE: FCX) between February 15, 2022 and September 24, 2025, both dates inclusive (the "Class Period"), of the important January 12, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

SO WHAT: If you purchased Freeport-McMoRan securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Freeport class action, go to https://rosenlegal.com/submit-form/?case_id=45553 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 12, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Freeport-McMoRan did not adequately ensure safety at the Grasberg Block Cave mine in Indonesia; (2) the lack of proper safety precautions constituted a heightened risk that could foreseeably lead to the death of Freeport's workers; (3) this constituted an undisclosed heightened risk of regulatory, litigation, and reputational risk; and (4) as a result, defendants' statements about Freeport-McMoRan's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Freeport class action, go to https://rosenlegal.com/submit-form/?case_id=45553 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276111

November 26, 2025 7:15 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - November 26, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and September 17, 2025, both dates inclusive (the "Class Period") of the important December 29, 2025 lead plaintiff deadline.

SO WHAT: If you purchased DexCom securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the DexCom class action, go to https://rosenlegal.com/submit-form/?case_id=28133 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. If you wish to serve as lead plaintiff, you must move the Court no later than December 29, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) DexCom had made material design changes to the G6 and G7 continuous glucose monitoring ("CGM") systems that were unauthorized by the U.S. Food and Drug Administration (the "FDA"); (2) the foregoing design changes rendered the G6 and G7 less reliable than their prior iterations, presenting a material health risk to users relying on those devices for accurate glucose readings; (3) accordingly, defendants' purported enhancements to the G7, as well as the device's reliability, accuracy, and functionality, were overstated; (4) Defendants downplayed the true scope and severity of the issues and health risks posed by adulterated G7 devices; (5) all the foregoing subjected DexCom to an increased risk of heightened regulatory scrutiny and enforcement action, as well as significant legal, reputational, and financial harm; and (6) as a result, defendants' public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the DexCom class action, go to https://rosenlegal.com/submit-form/?case_id=28133 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276106

In the latest close session, MongoDB (MDB - Free Report) was down 1.65% at $326.27. The stock trailed the S&P 500, which registered a daily gain of 0.69%. Meanwhile, the Dow experienced a rise of 0.67%, and the technology-dominated Nasdaq saw an increase of 0.82%.

The stock of database platform has fallen by 1.4% in the past month, lagging the Computer and Technology sector's gain of 0.07% and the S&P 500's loss of 0.31%.

Analysts and investors alike will be keeping a close eye on the performance of MongoDB in its upcoming earnings disclosure. The company's earnings report is set to go public on December 1, 2025. The company is expected to report EPS of $0.79, down 31.9% from the prior-year quarter. Meanwhile, the latest consensus estimate predicts the revenue to be $591.22 million, indicating a 11.68% increase compared to the same quarter of the previous year.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $3.7 per share and revenue of $2.35 billion, indicating changes of +1.09% and +17.31%, respectively, compared to the previous year.

Investors should also note any recent changes to analyst estimates for MongoDB. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.55% upward. MongoDB is currently sporting a Zacks Rank of #2 (Buy).

From a valuation perspective, MongoDB is currently exchanging hands at a Forward P/E ratio of 89.58. This valuation marks a premium compared to its industry average Forward P/E of 28.61.

It's also important to note that MDB currently trades at a PEG ratio of 5.72. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The average PEG ratio for the Internet - Software industry stood at 1.86 at the close of the market yesterday.

The Internet - Software industry is part of the Computer and Technology sector. At present, this industry carries a Zacks Industry Rank of 71, placing it within the top 29% of over 250 industries.

The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.

These are historic days for the company, following its first FDA approval.

The stock of biotech Arrowhead Pharmaceuticals (ARWR +23.34%) experienced a serious Hump Day jump. On the Wednesday before Thanksgiving, the company's shares rose by more than 23%, thanks largely to its latest earnings release.

A flying arrow
The previous day at market close, Arrowhead took the wraps off its full-year, fiscal 2025 results. The company's revenue for the period exceeded $829 million, primarily driven by an influx of licensing and collaboration funds, which was significantly higher than the $3.6 million reported in 2024.

Image source: Getty Images.

It also narrowed attributable net loss to $1.6 million, compared to the year-ago deficit of $599 million.

The most significant event for Arrowhead hasn't been its annual earnings release, though. Earlier this month, the U.S. Food and Drug Administration (FDA) approved its Redemplo for the treatment of adults with familial chylomicronemia syndrome (FCS). This is a rare genetic disorder that impairs the body's ability to metabolize fats. Redemplo is Arrowhead's first FDA nod.

Today's Change

(

23.34

%) $

10.92

Current Price

$

57.71

Coming soon to a pharmacy near you
These are exciting and memorable times for Arrowhead, which is in front of adding a new revenue stream with Redemplo. Meanwhile, its all-important collaborations are also bringing in funds, and should continue to do so as it gears up for commercializing the new drug. This is a company on the move, and therefore a stock for investors to watch -- especially biotech aficionados.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

CALGARY, Alberta, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Acceleware® Ltd. (“Acceleware” or the “Company”) (TSX-V: AXE) announces financial and operating results for the three and nine months ended September 30, 2025. This news release should be read in conjunction with the Company’s unaudited interim condensed financial statements and the accompanying notes for the nine months ended September 30, 2025, and management’s discussion and analysis (“MD&A”) thereto, together with the audited financial statements for the year ended December 31, 2024, notes and MD&A thereto, all of which are available on Acceleware’s website at www.acceleware.com or on www.sedarplus.ca.

Highlights for the Three and Nine Months Ended September 30, 2025

Financial Highlights:

 Three Months EndedNine Months Ended   September 30,
2025 September 30,
2024  September 30,
2025 September 30,
2024 Revenue$53,770 1,259,315 $686,519 3,314,956 Comprehensive (loss) income$(578,487) 856,500 $(1,674,830) 1,150,443 R&D expenditures$211,725 (196,809) $899,149 444,511 
Operational Highlights:

Acceleware’s goal is to enhance western Canadian resources by helping producers increase production and reduce operating costs by using the Company’s innovative electromagnetic RF heating applications.

RF XL 2.0
As part of the previously announced strategy to drive shareholder value, Acceleware began the process of securing farm-in agreements for commercial demonstration of its next generation RF XL 2.0 technology. Acceleware is in detailed discussion with several companies regarding multiple assets in both Saskatchewan and Alberta in geological horizons known as “Lloydminster Mannville Stack”.

The Company is also working in parallel to secure funding. Accordingly, the Company is in discussion with several potential industry and government funders. Acceleware has confirmed that the expected cost to complete the RF XL 2.0 Pilot would be approximately $5 to $6 million including contingency and depending on location. Recently the Company received conditional approval from the Saskatchewan Petroleum Innovation Incentive (“SPII”) program. The SPII program would provide a transferable royalty credit equal to 25 percent of eligible project costs from a future RF XL 2.0 Pilot carried out in the province. Approval is conditional on entering into a project agreement with Saskatchewan Ministry of Energy and Resources within two years.

The RF XL 2.0 design is complete and ready for manufacturing and deployment. RF XL 2.0 includes a new, fully sealed, continuous tubing based sub-surface design developed by Acceleware. It eliminates the possibility of water ingress through a robust leak-proof design, dramatically simplifies deployment, and reduces per well capital costs by an estimated 30 percent compared to RF XL 1.0 as deployed at the Marwayne pilot. Further benefits of RF XL 2.0 include reduced manufacturing costs; reduced well design and well completion costs; quicker well completion time; simpler and less costly wellhead design; and a safer wellhead operating environment.  

Critical Minerals and Amine Regeneration
In addition to RF XL 2.0, Acceleware’s strategy includes a focused investment plan that targets critical minerals processing and amine regeneration.

In Q3 2025, the Company continued to work with the International Minerals Innovation Institute (IMII) and its participating members on developing a Phase 3 proposal for the design, construction and testing of a new, larger-scale prototype dryer for potash and potash fines. Sanctioning could occur later this year. IMII’s minerals industry members include BHP, Cameco Corporation, Mosaic Company, Nutrien Ltd., Fission Uranium Corp. and The Uranium Corp. During Q3 2025, Acceleware secured a paid feasibility study contract from a major international miner for a second promising mineral processing application. In addition, Acceleware’s engineering team completed additional lab testing of a proof-of-concept amine RF regeneration system, with positive results. Discussions on potential Canadian and European Union collaboration and partnerships to further develop the technology are underway.

Financings
In Q3 2025, the Company closed the two tranches of a non-brokered private placement of units (the “Units”) and distributed a total of 10,003,342 Units, at a price of $0.10 per Unit, for total gross proceeds of $1 million. Each Unit consists of one common share of the Company and one common share purchase warrant of the Company. Each warrant entitles the holder of the warrant to acquire one common share, at an exercise price of $0.20, which will expire 24 months from the date of issuance. If the common shares trade at a closing price at or greater than $0.30 per common share for a period of 30 consecutive trading days, Acceleware may accelerate the expiry date of the warrants by giving notice to the holders thereof, and in such case, the warrants will expire on the 30th day after the date on which such notice is given by Acceleware.

Additionally, in Q3 2025, the Company closed Units for debt transactions to settle $186 thousand in certain trades payable, management fees and interest payable on convertible debentures of the Company by issuing 1,863,375 Units at a deemed price of $0.10 per Unit.

QUARTER IN REVIEW
Revenue of $54 thousand was recorded in the three months ended September 30, 2025 (“Q3 2025”) compared to $1.3 million in the three months ended September 30, 2024 (“Q3 2024”) and $202 thousand in the previous quarter ended June 30, 2025 (“Q2 2025”). Higher revenue in Q3 2024 was associated with deferred revenue recognized relating to a contract with one oil sands producer for the RF XL Marwayne Pilot. Higher revenue in Q2 2025 was related to services revenue earned related to the Company’s potash dryer project, for which there was no related revenue in Q3 2025 as the Company is negotiating the next phase of the project with the customer.

Total comprehensive loss for Q3 2025 was $578 thousand compared to a comprehensive income of $857 thousand for Q3 2024 and comprehensive loss of $714 thousand for Q2 2025. The increase in comprehensive loss in Q3 2025 compared to Q3 2024 was due to the recognition of deferred revenue in Q3 2024 noted above, and higher government assistance for R&D in Q3 2024. Comprehensive loss in Q2 2025 was higher due to higher general and administrative (“G&A”), research and development (“R&D”) and finance expenses despite higher services revenue. Finance expense includes interest expense on convertible debentures and notes payable which are funding the Company’s working capital. Comprehensive income in all periods was impacted by changes in value of the derivative financial instruments embedded within the convertible debenture. The changes in derivative value are driven primarily by the fluctuation in the Company’s share price.

R&D expenses incurred in Q3 2025 were $212 thousand compared to negative $197 thousand in Q3 2024 and $267 thousand in Q2 2025. There was $54 thousand in government assistance received in Q3 2025, $nil in Q2 2025 and $650 thousand received in Q3 2024, which resulted in overall negative R&D for Q3 2024. R&D spending in Q3 2025 was related to testing of the Company’s amine regeneration proof-of-concept, next generation potash dryer designs, and further refinement of RF XL 2.0. Spending in Q2 2025 was related to the IMII dryer for potash ore and included lab engineering, designing and testing, data analysis, and partner consultations, as well as engineering on the next iteration of RF XL 2.0 and the RF XL 2.0 Pilot. R&D spending in Q3 2024 was related to the RF XL 2.0.

G&A expenses incurred in Q3 2025 were $245 thousand compared to $446 thousand in Q3 2024 and $327 thousand in Q2 2025. There were lower payroll, marketing and professional fee expenses in Q3 2025 compared to both Q3 2024 and Q2 2025 as the Company continues to prioritize cost control and rationalize G&A given uncertain economic conditions.

YEAR TO DATE IN REVIEW
Revenue of $687 thousand was generated in the nine months ended September 30, 2025, compared to $3.3 million for the nine months ended September 30, 2024. Revenue for the nine months ended September 30, 2024, included $2.85 million in deferred revenue recognized related to the RF XL Marwayne Pilot. Revenue for the nine months ended September 30, 2025, was primarily services revenue related to the potash dryer and RF XL, software revenue and maintenance revenue.

Total comprehensive loss for the nine months ended September 30, 2025, was $1.7 million compared to comprehensive income of $1.1 million for the nine months ended September 30, 2024. Comprehensive income was higher in the nine months ended September 30, 2024, due to recognition of deferred revenue as noted above and higher government assistance for R&D. There are fluctuations in both periods related to changes in fair value of the derivative financial instruments embedded in the Company’s convertible debentures.

R&D expenses for the nine months ended September 30, 2025, were $899 thousand compared to $445 thousand incurred during the nine months ended September 30, 2024, due to lower government assistance. Government assistance of $54 thousand was received in the nine months ended September 30, 2025, compared to $1.2 million for the nine months ended September 30, 2024, as the RF XL Marwayne Pilot neared completion.

G&A expenses incurred during the nine months ended September 30, 2025, were $824 thousand compared to $1.3 million for the nine months ended September 30, 2024, due to lower payroll, marketing, office, and professional fees as the Company is actively rationalizing G&A costs.

As at September 30, 2025, Acceleware had negative working capital of $3.6 million (December 31, 2024 – negative working capital of $3.4 million) including cash and cash equivalents of $461 thousand (December 31, 2024 – $272 thousand). The decrease in negative working capital and increase in cash is attributable to the closing of private placement of Units and Units for debt transactions noted below.

In the interest of matching cash requirements with a combination of cash generated from operations, external funding, and capital raising activities, the Company actively manages its cash flow and investments in new products. Acceleware intends to maximize cash generated from operations through several initiatives which include continuing to focus on higher gross margin software products that are marketed through a combination of direct and reseller models; minimizing operating expenses where possible; and limiting capital expenditures. As the Company continues to develop its RF Heating technology, new R&D investments will be financed through a combination of internal cash flow from software and maintenance revenue, project funding agreements, government assistance and external financing, when available.

ABOUT ACCELEWARE

Acceleware is an advanced electromagnetic heating company with cutting-edge RF power-to-heat solutions for large industrial applications. Its technologies enable electrification and decarbonize industrial process heat applications while reducing costs. 

  The Company is working to use its patented, field proven Clean Tech Inverter to materially improve the efficiency of amine regeneration. It has partnered with a consortium of world-class potash producers to decarbonize potash ore drying and other critical mineral processes. Acceleware is also developing additional process heat applications and partnerships for RF heating.  

Acceleware’s RF XL is a patented low-cost, low-carbon RF thermal technology for enhanced oil production for heavy oil. This approach is materially different from any existing recovery technique.

Acceleware is a public company listed on the TSXV under the trading symbol “AXE”.   

NOTE REGARDING FORWARD-LOOKING INFORMATION AND OTHER ADVISORIES

This news release contains “forward-looking information” within the meaning of Canadian securities legislation. Forward-looking information generally means information about an issuer’s business, capital, or operations that are prospective in nature, and includes disclosure about the issuer’s prospective financial performance or financial position. 

The forward-looking information in this press release can be identified by terms such as “believes”, “could”, “estimates”, “plans”, “potential”, and “will”, and includes information about, the expected commercialization of RF XL and other EM Powered Heat technology, the expected cost of the RF XL 2.0 Pilot, the timing of the execution of the RF XL 2.0, expected financing required for the RF XL 2.0 Pilot redeployment, the anticipated economic and societal benefits of the RF XL and RF heating technology, and the future development plans related to potash ore drying and amine regeneration prototypes. Acceleware assumes that current cost estimates are accurate, current timelines will not be delayed by either internal or external causes, that research and development effort including the commercial-scale test plans will result in commercial-ready products, and that future capital raising efforts will be successful.  

Actual results may vary from the forward-looking information in this press release due to certain material risk factors. These risk factors are described in detail in Acceleware’s continuous disclosure documents, which are filed on SEDAR at www.sedar.com. 

Acceleware assumes no obligation to update or revise the forward-looking information in this press release, unless it is required to do so under Canadian securities legislation. 

DISCLAIMER

This press release is intended for distribution in Canada only and is not intended for distribution to United States newswire services or dissemination in the United States. 

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. 

For more information: 

Geoff Clark 
Tel: +1 (403) 249-9099 
[email protected] 

Spot gold edged higher. Expectations of a rate cut is rising following dovish comments from policymakers, ANZ said.

In a case of exquisite timing, the company released a highly encouraging financial update.

What a difference a day can make in the cryptocurrency world. On Wednesday, following a several days-long rout, digital coins and tokens staged an impressive comeback. Swept along with this were a great many cryptocurrency stocks.

Happily for CleanSpark (CLSK +13.79%) and its investors, the eagerly diversifying Bitcoin (BTC +3.56%) miner was among these titles. Fueled by the general crypto sentiment, plus an encouraging earnings report, the company's shares notched a nearly 14% price gain on the day.

Big gains in 2025
Just after market close Tuesday, CleanSpark published its full-year fiscal 2025 results, which it described as "transformative."

Image source: Getty Images.

That's hype, but still the company posted some encouraging numbers. The year saw it collect just over $766 million in revenue, which was double and then some the $379 million of the previous annual figure. Net income according to generally accepted accounting practices (GAAP) was $364.5 million ($1.25 per share), quite an improvement over the 2024 loss of $145.8 million.

Although it's making a concentrated push deeper into the data center segment, CleanSpark is still heavily associated with its Bitcoin mining operations. The company reported it held $1.2 billion worth of the coin at the end of fiscal 2025.

Today's Change

(

13.79

%) $

1.63

Current Price

$

13.45

A good day to release good news
Timing was definitely on CleanSpark's side on Wednesday, as Bitcoin blasted higher that morning, vaulting above the $90,000 level in the afternoon and (as of this writing, at least) staying there. Many crypto-heads clearly felt the leading coin (and others) were oversold and piled in, while hopes keep rising for a Federal Reserve (Fed) rate cut next month; such adjustments usually benefit cryptos.

While CleanSpark's results were impressive in many ways, to me, the jury is still out on its diversification efforts. Other cryptocurrency companies are making similar moves to expand their data center businesses, and so far, it's too early to judge which ones will be successful and to what extent. Given that, I think CleanSpark is a stock for dedicated crypto bulls only.

Stellar’s XLM continued its steady upward momentum through Tuesday’s trading session, supported by strong technical signals and a banking-sector catalyst that boosted investor confidence. The token moved within a tight $0.0132 range yet still posted 5.4% intraday volatility, showing controlled but persistent buyer interest. Momentum picked up late Monday around 15:00 UTC when XLM saw an unusually heavy influx of volume, with 38 million tokens traded—well above the 24-hour average of 21.7 million. Overall trading activity ended the session roughly 45% higher than normal, a surge that helped propel XLM decisively past the key $0.2460 resistance level.

The bullish impulse aligned with reports that U.S. Bancorp, the fifth-largest bank in the U.S., has chosen Stellar’s blockchain for institutional stablecoin testing. This development strengthened market sentiment by signaling increasing enterprise-level interest in Stellar’s network. Volume behavior also supported the rally, especially during the 07:00–09:00 UTC breakout window, where activity patterns suggested clear institutional participation. Even minor pullbacks held comfortably above rising support levels, reinforcing the strength of the ascending trend.

Late-session trading added to the upward pressure, with XLM climbing from $0.2495 to $0.2522 in the final hour as volumes exceeded 850,000 tokens. A sharp push between 13:37 and 13:42 UTC confirmed the token’s move above the psychological $0.2500 mark, a level traders had been watching closely.

Technical conditions remain favorable for continuation. Primary support tracks along an ascending trendline connecting the overnight lows, while resistance at $0.2500 has now been cleared. Traders are eyeing the next cycle high target at $0.2556, with immediate support anchored around the $0.2495 breakout point. The consistent volume surge, trend structure, and controlled consolidation all point to ongoing accumulation rather than speculative spikes, suggesting XLM may retain its bullish bias in the sessions ahead.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>

Ethereum continues to trade below the critical $3,000 level as selling pressure intensifies and fear dominates sentiment across the crypto market. The broader downturn has pushed ETH nearly 40% below its August all-time high, raising concerns that the asset may be entering a prolonged bearish phase. Analysts who were once confident in a continued rally are now shifting their tone, warning that market structure, volatility, and liquidity conditions are beginning to resemble early-stage bear market behavior.

At the same time, investor confidence is being further tested by fresh on-chain activity showing large holders reducing exposure. According to data from Lookonchain, an Ethereum ICO participant has sold another 20,000 ETH, valued at approximately $58.14 million, through FalconX just a few hours ago.

Ethereum ICO Whale Transactions | Source: Lookonchain
With selling pressure accelerating, derivatives sentiment weakening, and long-term holders beginning to reduce positions, Ethereum now sits at a pivotal moment. Bulls must reclaim the $3,000 region to stabilize momentum, while bears argue that a deeper correction could unfold if support continues to erode.

ICO Whale Selling Raises Pressure as Ethereum Awaits Direction
According to Lookonchain, the wallet behind the latest sale — identified as address 0x2eb0 — is no ordinary holder. This Ethereum OG received 254,908 ETH during the ICO, paying just $79,000 at the time. At today’s prices, that allocation is worth roughly $757 million, highlighting the scale of unrealized gains still held by early participants. The recent sale of 20,000 ETH suggests that even long-standing holders with substantial profit cushions are beginning to offload coins, adding to the already fragile market environment.

Ethereum ICO Whale original holdings | Source: Lookonchain
This selling activity is particularly impactful given the current sentiment. Ethereum has already fallen sharply from its highs, leverage has unwound across derivatives markets, and retail confidence has thinned. When an early participant with a cost basis near zero begins distributing, it sends a psychological signal that further downside is possible. Yet, some analysts argue that these sales may simply represent portfolio rotation rather than a long-term bearish stance.

The coming days will be decisive, as investors watch whether Ethereum can stabilize and rebound or if selling pressure accelerates. A recovery above $3,000 could revive optimism and reset momentum, while continued weakness risks confirming a deeper downtrend for both ETH and the broader market.

Breakdown, Weak Structure, and Fragile Bounce Attempt
Ethereum’s weekly chart reveals a clear deterioration in trend structure following the sharp rejection from the $4,400 region and the subsequent breakdown below the $3,200 support zone. The selloff pushed ETH toward the mid-$2,700s before a modest rebound, but the price remains below key moving averages, signaling that momentum continues to favor sellers.

ETH testing key demand level | Source: ETHUSDT chart on TradingView
The 50-week moving average has rolled over, while the 100-week and 200-week moving averages now sit overhead, forming layered resistance that could cap any recovery attempts in the short term.

Volume during the decline expanded noticeably, indicating active distribution rather than passive drifting. The most recent candle shows a small bounce, but with no strong volume follow-through, suggesting hesitation and lack of conviction among buyers.

For Ethereum to regain bullish structure, reclaiming the $3,000–$3,200 area is essential, as this zone acted as a pivotal support throughout earlier phases of the cycle and now threatens to flip into resistance.

Featured image from ChatGPT, chart from TradingView.com

In an ambitious move by the Solana development team, a proposal has been put forward to significantly cut the inflation rate of SOL, potentially lowering its issuance by as much as 30%. Slated for discussion and review by the community, this proposal could redefine the economic dynamics of the Solana blockchain.

Thailand orders Worldcoin to halt operations and delete user data following data protection violations and iris scan concerns.

MON has continued its upward trajectory, gaining significant attention after Monad successfully launched its mainnet on November 24. The milestone has boosted confidence in the project, with the network’s enhanced efficiency, improved scalability, and clear development roadmap helping drive demand for the native token.

The broader crypto market has also strengthened, rising 3.37% in the past 24 hours despite a 7-day decline. Bitcoin climbed past $89,000, while Ethereum surged above $3,000, helping fuel optimism across major altcoins, including XRP and Solana.

Monad’s mainnet launch marked a major evolution for the project. Alongside the rollout, Monad executed its token generation event, releasing 10% of its fixed 100 billion total supply. Interest soared immediately, with the number of MON holders tripling within 24 hours. This rapid adoption underscores growing trust in the network, as new users and investors seek early exposure to the growing ecosystem. Since launch, the blockchain has already processed over 2 million transactions, signaling strong network activity.

MON’s price has reacted positively to the momentum. After hitting a high near $0.05, the token is currently trading at $0.04705, holding firmly above the key $0.047 support level with a 20% daily gain. Its rising utility and growing user base have positioned MON as one of the week’s standout performers. Analysts note that MON’s lack of a major exchange listing—such as Binance—has contributed to more organic price action, allowing the token to avoid volatility typically seen after high-profile listings.

Looking ahead, bullish sentiment continues to build. If demand remains strong, MON could break through the $0.05 resistance and potentially climb toward the $0.10 target some analysts are forecasting. However, a pullback remains possible; if the price falls below $0.040, MON could revisit lower support near $0.035.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>